JoVE Logo
Faculty Resource Center

Sign In

Summary

Abstract

Introduction

Protocol

Representative Results

Discussion

Acknowledgements

Materials

References

Medicine

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published: May 25th, 2020

DOI:

10.3791/60392

1Cardiology Division, Department of Medicine, Queen Mary Hospital, University of Hong Kong, 2Shenzhen Institutes of Research and Innovation, University of Hong Kong
* These authors contributed equally

We sought to establish a swine model of heart failure induced by left circumflex artery blockage and rapid pacing to test the effect and safety of intramyocardial administration of stem cells for cell-based therapies.

Although advances have been achieved in the treatment of heart failure (HF) following myocardial infarction (MI), HF following MI remains one of the major causes of mortality and morbidity around the world. Cell-based therapies for cardiac repair and improvement of left ventricular function after MI have attracted considerable attention. Accordingly, the safety and efficacy of these cell transplantations should be tested in a preclinical large animal model of HF prior to clinical use. Pigs are widely used for cardiovascular disease research due to their similarity to humans in terms of heart size and coronary anatomy. Therefore, we sought to present an effective protocol for the establishment of a porcine chronic HF model using closed-chest coronary balloon occlusion of the left circumflex artery (LCX), followed by rapid ventricular pacing induced with pacemaker implantation. Eight weeks later, the stem cells were administered by intramyocardial injection in the peri-infarct area. Then the infarct size, cell survival, and left ventricular function (including echocardiography, hemodynamic parameters, and electrophysiology) were evaluated. This study helps establish a stable preclinical large animal HF model for stem cell treatment.

Cardiovascular diseases, coronary artery disease (CAD) in particular, remain the major cause of morbidity and mortality in Hong Kong and worldwide1. In Hong Kong, a 26% increase from 2012 to 2017 of the number of CAD patients treated under the Hospital Authority was projected2. Among all CADs, acute myocardial infarction (MI) is a leading cause of death and subsequent complications, such as heart failure (HF). These contribute to significant medical, social, and financial burdens. In patients with MI, thrombolytic therapy or primary percutaneous coronary intervention (PCI) is an effective therapy in preserving life, but ....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

All animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and regulations of the University of Hong Kong, and the protocol was approved by the Committee on the Use of Live Animals in Teaching and Research (CULTAR) at the University of Hong Kong.

NOTE: Female farm pigs weighing 35-40 kg (9-12 months old) were used for this study. The flowchart of this experiment is shown in

Log in or to access full content. Learn more about your institution’s access to JoVE content here

Mortality
A total of 24 pigs were used in this study. Three of them died during MI induction because of sustained VT. One animal died in the open-heart surgery for cell injection because of wound bleeding. Two animals died because of severe infection. Two animals were excluded because of slight EF reduction (LVEF reduction > 40% of baseline). As a result, 16 animals completed the whole study protocol.

.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

Standard animal models are of paramount importance to understand the pathophysiology and mechanisms of diseases and test novel therapeutics. Our protocol establishes a porcine model of HF induced by left circumflex artery blockage and rapid pacing. Eight weeks after the induction of MI, the animals developed significant impairment of LVEF, LVEDD, LVESD, +dP/dt, and ESPVR. This protocol also tests the administration method of stem cell therapy for heart regeneration by intramyocardial injection. The infarct size, and card.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

The authors acknowledge Alfreda and Kung Tak Chung for their excellent technical support during the animal experiments.

....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

NameCompanyCatalog NumberComments
AmiodaroneMylan--
Anaesthetic machines and respiratorDragerFabius plus XL-
AngiocathBecton Dickinson381147-
Anti-human nuclear antigenabcamab19118-
Axio Plus image capturing systemZeissAxioskop 2 PLUSAxioskop 2 plus
AxioVision Rel. 4.5 softwareZeiss--
BaytrilBayer-enrofloxacin
BetadineMundipharma--
CardioLab Electrophysiology Recording SystemsGE HealthcareG220f-
Culture mediaMesenCult05420-
CyclosporineNovartis--
DefibrillatorGE HealthcareCardioServ-
DorminalTEVA--
Echocardiographic systemGE VingmedVivid i-
EchoPac softwareGE Vingmed--
Electrophysiological catheterCordis Corp--
Embozene MicrosphereBoston Scientific17020-S1700 μm
Endotracheal tubeVet CareVCPET70PCWSize 7
EthanolVWR chemicals20821.33-
FormalinSigmaHT50132010%
IVC balloon Dilatation CatheterBoston Scientific3917112041Mustang
JR4 guiding catheterCordis Corp672082006F
LidocaineQuala--
MersilkEthiconW5842-0
Metoprolol succinateWockhardt--
MicrotomeLeicaRM2125RT-
Mobile C arm fluoroscopy equipmentGE HealthcareOEC 9900 Elite-
PacemakerSt Jude MedicalPM1272Assurity MRI pacemaker
Pacemaker generatorSt Jude MedicalMerlln model 3330-
Pressure-volume catheterCD LeycomCA-71103-PL7F
Pressure–volume signal processorCD LeycomSIGMA-M-
Programmable StimulatorMedtronic Inc5328-
PTCA Dilatation balloon CatheterBoston ScientificH7493919120250MAVERICK over the wire
RamiprilTEVA--
Sheath introducerCordis Corp504608X8F, 9F, 12F
SteroidVersus Arthritis--
TemgesicNindivior-buprenorphine
Venous indwelling needleTERUMOSR+OX2225C22G
VicrylEthiconVCP320H2-0
XylazineAlfasan International B.V.--
ZoletilVirbac New Zealand Limited-tiletamine+zolezepam

  1. Mozaffarian, D., et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 131, e29 (2015).
  2. Hospital Authority. . Hospital Authority Statistical Report 2013. , (2013).
  3. Cung, T. T., et al. Cyclosporine before PCI in Patients with Acute Myocardial Infarction. The New England Journal of Medicine. 373 (11), 1021-1031 (2015).
  4. Liao, S. Y., et al. Proarrhythmic risk of embryonic stem cell-derived cardiomyocyte transplantation in infarcted myocardium. Heart Rhythm. 7, 1852-1859 (2010).
  5. Liao, S. Y., et al. Overexpression of Kir2.1 channel in embryonic stem cell-derived cardiomyocytes attenuates posttransplantation proarrhythmic risk in myocardial infarction. Heart Rhythm. 10, 273-282 (2013).
  6. Liu, Y., et al. Thoracic spinal cord stimulation improves cardiac contractile function and myocardial oxygen consumption in a porcine model of ischemic heart failure. Journal of Cardiovascular Electrophysiology. 23, 534-540 (2012).
  7. Liao, S. Y., et al. Improvement of Myocardial Function Following Catheter-Based Renal Denervation in Heart Failure. JACC: Basic to Translational Science. 2 (3), 270-281 (2017).
  8. Liao, S. Y., et al. Remodelling of cardiac sympathetic re-innervation with thoracic spinal cord stimulation improves left ventricular function in a porcine model of heart failure. Europace. 17 (12), 1875-1883 (2015).
  9. Daehnert, I., Rotzsch, C., Wiener, M., Schneider, P. Rapid right ventricular pacing is an alternative to adenosine in catheter interventional procedures for congenital heart disease. Heart. 90 (9), 1047-1050 (2004).
  10. Hála, P., et al. Tachycardia-Induced Cardiomyopathy as a Chronic Heart Failure Model in Swine. Journal of Visualized Experiments. (132), e57030 (2018).
  11. Santoso, T., et al. Endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic heart failure: a randomized placebo-controlled trial (END-HF). Journal of Cardiovascular Translational Research. 7, 545-552 (2014).
  12. Traverse, J. H., et al. Cardiovascular Cell Therapy Research Network. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. Journal of the American Medical Association. 306, 2110-2119 (2011).
  13. Traverse, J. H., et al. Cardiovascular Cell Therapy Research Network (CCTRN). Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. Journal of the American Medical Association. 308, 2380-2389 (2012).
  14. de Jong, R., Houtgraaf, J. H., Samiei, S., Boersma, E., Duckers, H. J. Intracoronary stem cell infusion after myocardial infarction. A meta-analysis and update on clinical trials. Circulation: Cardiovascular Interventions. 7, 156-167 (2014).
  15. Nowbar, A. N., et al. DAMASCENE writing group. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. British Medical Journal. 348, g2688 (2014).
  16. Kanelidis, A. J., Premer, C., Lopez, J., Balkan, W., Hare, J. M. Route of Delivery Modulates the Efficacy of Mesenchymal Stem Cell Therapy for Myocardial Infarction: A Meta-Analysis of Preclinical Studies and Clinical Trials. Circulation Research. 120 (7), 1139-1150 (2017).
  17. Hou, D., et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation. 112 (9 Suppl), I150-I156 (2005).
  18. Hu, X., et al. A Large-Scale Investigation of Hypoxia-Preconditioned Allogeneic Mesenchymal Stem Cells for Myocardial Repair in Nonhuman Primates: Paracrine Activity Without Remuscularization. Circulation Research. 118, 970-983 (2016).
  19. Chong, J. J., et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature. 510, 273-277 (2014).
  20. Martens, A., et al. Substantial early loss of induced pluripotent stem cells following transplantation in myocardial infarction. Artificial Organs. 38, 978-984 (2014).
  21. Shiba, Y., et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature. 538, 388-391 (2016).

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved